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1.1. Newborn screening
Phenylketonuria (PKU) is identiﬁed through national newborn
screening programs [1]. The ﬁrst efﬁcient test for hyperphenylalani-
nemia (HPA) was a bacterial inhibition assay developed by Robert
Guthrie [2]. The test was based on Bacillus subtilis, which requires
phenylalanine (Phe) for growth. The Guthrie test was very useful
for mass screening as the dried blood spot (DBS) can be obtained in
the hospital or a doctor's ofﬁce using a standardized ﬁlter paper
(“Guthrie card”) and mailed to reference laboratories in an envelope.
Tandem mass-spectrometry (TMS) was developed as a fast method
for achieving reliable and quantitative determination of concentra-
tions of amino acids in small volumes of blood or plasma [3]. This
method produces a lower rate of false positive results, by measuring
levels of both Phe and Tyr and providing the Phe/Tyr ratio, and thus
requires fewer resources to follow up such cases. In addition, other in-
born errors of metabolism can be identiﬁed simultaneously.
All infants should be screened for PKU within the ﬁrst days of life,
in order to allow timely dietary intervention to protect children with
PKU from neurological damage. Where screening is carried out in ma-
ternity wards, the blood sample is usually obtained between days 2
and 5; in general, however, screening is carried out mostly between
the ages of 2 and 7 days [4]. In the U.S., samples are typically obtained
at 24–48 h. A commonly used Phe cut-off level for diagnosis of PKU is
120–130 μmol/L (with a Phe/Tyr ratio N2), with TMS employed [5].
Concern has been expressed that screening too early, associated
with a shift towards earlier discharge from maternity wards, can pro-
vide a false negative result, as there will have been insufﬁcient oppor-
tunity for Phe from the diet to build up to diagnostic (and toxic)
levels. It is currently accepted that the sensitivity of screening in a
healthy neonate is adequate before 24 h of life, especially where the
screening test involves measurement of Phe/Tyr ratios to increase
sensitivity relative to Phe measurement alone [3,6]. However, as the
pretreatment level is often used as a diagnostic parameter for the
classiﬁcation of the PKU phenotype new cut-offs have to be deter-
mined for classic and mild PKU and mild HPA when measuring the
Phe level so early.
Some infants, particularly those born prematurely, may demon-
strate immaturity of enzyme systems involved in amino acid metabo-
lism, resulting in a transient elevation of blood Phe to a level sufﬁcient
to test positive in a PKU screening test. The results of early PKU screen-
ing should also be interpreted with caution in sick neonates or in ne-
onates under parenteral nutrition or blood transfusion, and a second
screening test should be sent if it is unclear whether the child had suf-
ﬁcient protein intake when the ﬁrst test was collected.1.2. Differential diagnosis
About 2% of all Phe level elevations detected by the newborn
screening are due to disorders in BH4 metabolism, highlighting the
importance of always considering the differential diagnosis for
every even slightly elevated blood Phe level [7]. Frequency of BH4 de-
ﬁciency is higher in some countries where the rate of consanguineous
marriages tends to maintain the presence of genetic disorders withinfamilies, e.g. Turkey or Saudi Arabia [8]. BH4 deﬁciencies are more se-
vere than PKUwith regard to their response to therapy and treatment
is substantially different. Low-Phe diet is not effective and early sub-
stitution with dopamine and serotonin precursors, as well as with the
synthetic BH4 (sapropterin dihydrochloride) is crucial for a good out-
come. Analysis of DBS or urine for neopterin and biopterin and mea-
surement of dihydropteridine reductase (DHPR) activity in the DBS is
essential for the exact diagnosis and should be performed as early as
possible. A BH4 loading test and measurement of neurotransmitter
metabolites, pterins, and folates in cerebrospinal ﬂuid add further im-
portant information about the severity of the disease [9].
In patients with BH4 deﬁciency, the pattern of pterins is identical
in blood, urine, and CSF. The use of DBS on ﬁlter paper (Guthrie card)
is, however, more practical and allows measurement of pterins, DHPR
activity, and amino acids from a single specimen [10]. It is important
to know that patients with classic PKU excrete more pterins in urine
compared with healthy controls and the amount of excreted metabo-
lites is directly proportional to blood Phe levels. Diseases that cause
activation of the immune system (elevated neopterin), and antican-
cer therapy or rheumatic disease therapy with methotrexate (inhibi-
tion of DHPR), may interfere with the analytic procedures. Some
patients with DHPR deﬁciency show a normal blood or urinary neop-
terin and biopterin proﬁle. Therefore, DHPR activity measurement is
essential in all patients with HPA, regardless of pterin measurements.
Fig. 1 shows the algorithm for the diagnostic work-up of elevated
blood Phe levels. Table 1 summarizes the most important biochemical
parameters used in the differential diagnosis of HPA.1.3. BH4 loading test
The BH4 loading test was initially used to discriminate between
patients with elevated phenylalanine levels due to PAH deﬁciency
and patients with elevated Phe levels due to BH4 deﬁciency (enzyme
defects in the biosynthesis or regeneration of the cofactor BH4)
[11,12]. Thus, the loading test is an additional useful tool for the
early detection of BH4 deﬁciencies and it was used in Europe for al-
most 30 years. In addition, this test detects PKU patients responsive
to BH4 administration.
Detection of BH4-responsive PKU patients is important because
some PKU patients beneﬁt from oral administration of BH4 (saprop-
terin dihydrochloride) in that their blood Phe level decreases or
even normalizes under pharmacological therapy with BH4 [13]. The
phenomenon of BH4-sensitive PKUwas initially described in Japanese
patients, and conﬁrmed in retrospective and prospective studies with
large cohorts of patients [14–16]. Modalities of the BH4 challenge
vary in the literature from a 24-hour test with a single administration
of BH4 (10–20 mg/kg) to several weeks of administration with daily
or weekly monitoring of blood Phe levels [17,18].
There is general agreement that a reduction on blood Phe of at
least 30% in response to BH4 loading indicates a clinically signiﬁcant
effect, although in some centers a lower cut-off value may be deﬁned
for individual patients, or no speciﬁc cut-off value may be used [19].
The frequency of BH4-responsiveness is highest in patients with
mild (non-PKU) HPA, or mild PKU resulting from PAH mutations
that allow for residual enzyme activity [15,20]. Conversely, the re-
sponse rate among patients with classic PKU (little or no residual
Fig. 2. Proposed algorithms for the BH4 (sapropterin dihydrochloride) challenge,
screening, and initiating treatment in BH4-responsive PKU patients. A) Initial screening
test with blood Phe monitoring on the ﬁrst day and BH4 (sapropterin dihydrochloride)
administration (20 mg/kg) on two following days; B) Efﬁciency testing in BH4-repon-
sive patients over several weeks with BH4 doses adjusted individually according to Phe
tolerance and therapeutic blood Phe levels.
Fig. 1. Diagnostic ﬂow-chart for the laboratory diagnosis of PKU and BH4 deﬁciencies.
Modiﬁed according to Opladen et al. [10]. Dried blood spots (DBS) or random urine (U)
can be used for the differential diagnosis and depending on the proﬁle of neopterin
(Neo), biopterin (Bio), and primapterin (Pri) and dihydropteridine reductase (DHPR)
activity in DBS, diagnosis of following BH4 deﬁciencies can be established: GTP cyclo-
hydrolase I (GTPCH) deﬁciency (low or no detectable neopterin and biopterin), 6-
pyruvoyl-tetrahydropterin synthase (PTPS) deﬁciency (high neopterin and low or no
detectable biopterin), dihydropteridine reductase (DHPR) deﬁciency (normal neop-
terin and normal or elevated biopterin and no DHPR activity), and pterins-4a-
carbinolamine dehydratase (PCD) deﬁciency (elevated neopterin, low-normal biop-
terin, and elevated primapterin). n: normal.
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BH4 responsiveness have been identiﬁed and genotyping is a useful
additional tool for predicting responsiveness [21,22] (see below).
Fig. 2 summarizes the proposed procedure for the BH4 loading test
in Europe. In newborns the test should be performed before introduc-
ing the low-Phe diet and at elevated blood Phe levels (N400 μmol/L).
In infant or adult PKU patients on a Phe-restricted diet, the diet needs
to be modiﬁed by increasing the protein intake (egg or milk powder
before and during the test). Table 2 summarizes factors that may po-
tentially inﬂuence the outcome of the test.
An international online survey [23] with 92 participants from 30
different countries documented that in 62% of the metabolic centers
the BH4 loading test is an integral part of the diagnostic work-up
for PKU. The main reason for not using the BH4 test is either relatively
high costs or no availability of BH4 in some countries (78%). Most
centers use the BH4 test in all age groups (79%) and only in about
11% of the metabolic centers pregnant PKU women are tested. ATable 1
Biochemical parameters in dried blood spots (DBS) used in the differential diagnosis of
PKU and BH4 deﬁciencies.
Deﬁciency Neopterin Biopterin Primapterin DHPR activity Phe
PKU n- n- n n
GTPCH n n a
PTPS n n
PCD -n n
DHPR n n- a n
a Can be normal in the early neonatal period.dosage of 20 mg/kg is used in 92% of the centers and duration of the
test is quite variable: 24 h (33%), 48 h (24%), 72 h (16%), and about
26% run the test over 1–4 weeks, most of them from the U.S. with
test duration over at least 4 weeks. About half of the survey partici-
pants deﬁned BH4-responsiveness as both increase in tolerance for
dietary Phe (by a factor of two) and reduction in blood Phe levels
(by at least 30%), while the rest use only blood Phe reduction as
criterion.
1.4. Cerebrospinal ﬂuid investigation
BH4 deﬁciency inﬂuences the synthesis of catecholamines, seroto-
nin [24] and nitric oxide [25] in the central nervous system (CNS),
and measurement of their metabolites in cerebrospinal ﬂuid (CSF) is
important for the diagnosis of different forms (severe v. mild) of
BH4 deﬁciencies. Not only the absolute levels of 5-hydroxyindoleace-
tic acid and homovanillic acid in CSF, but also differences in the ratios
of neurotransmitter levels provide important diagnostic information
relating to the severity and outcome of BH4 deﬁciency [26].
2. Classiﬁcation
2.1. Phenylalanine loading test
Phenylalanine loading tests were applied since 1956 for the detec-
tion of heterozygotes in PKU families [27], until, in the late 1980s, thisTable 2
Factors potentially affecting the BH4 loading test.
■ BH4 dosage (higher sensitivity with 20 mg/kg v. 10 mg/kg)
■ Duration of the test (24–48 h for initial screening v. 4–8 weeks for efﬁciency)
■ Food intake (better GI absorption of BH4 with high calories food)
■ Age (outcome may be different in newborns v. adolescents v. adults)
■ Diet (better response to BH4 when out of diet and on higher blood Phe levels)
■ GI absorption (may be individually different; monitor blood BH4 levels)
■ Genotype
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and mutations [28]. Phenylalanine loading tests gained further inter-
est when Guthrie card mass screening uncovered not only the
expected cases of classic PKU but also variants of PKU [29]. Because
these variants were initially thought not to require dietary treatment,
a reliable discrimination of these phenotypes was needed. For practi-
cal and ethical reasons, in vivo
3
H or
14
C isotope studies [30] or inva-
sive testing such as enzyme assays from liver biopsies [31] were not
appropriate. Therefore, Blaskovics [32] developed in the mid-1960s
the standardized three day natural protein loading test with evapo-
rated milk that was applied at 6 months of age in the U.S. [33] and
German [34] PKU Collaborative Studies for classiﬁcation of PKU and
for genotype-phenotype analysis. With this test three principal
types of Phe blood level response, types 1, 2 and 3, were delineated
in both studies. Type 1 is characterized by a 72 h Phe beyond
1200 μmol/L and corresponds to classic PKU. Type 2 is deﬁned by a
spontaneous decline of Phe levels, despite continuation of loading,
from above 1200 μmol/L after day 2 to a 72 h Phe levels of 1200–
600 μmol/L. In both studies, about 10% of the patients belong to this
type. In type 3 the plasma Phe ﬂuctuates around 600 μmol/L and the
72 h Phe levels are b600 μmol/L. Clinically, it corresponds to mild
HPA. On a free diet, these patients (22% in the U.S., and 13% in the
German study) do not need a low-Phe treatment for normal mental
outcome [35].
Major successes of the Blaskovics loading test were (i) the discov-
ery of the type 2 response as an indicator of mutant enzyme activa-
tion by Phe [36], (ii) the delineation of the type 3 response as the
base for the decision to discontinue dietetic treatment, and (iii) its
use as a measure of in vivo phenotype for genotype–phenotype anal-
ysis. In contrast to its proven scientiﬁc value, the test has only limited
value for the dietetic treatment of patients with classic and mild PKU
because the Phe 72 value will not predict the current and future indi-
vidual dietary requirements (see below) and the patients may mani-
fest during the test signs of intoxication such as nausea, vomiting,
irritability, insomnia and EEG changes. The test is no longer necessary
[37] and has been replaced in practice by predictive molecular and
enzymatic classiﬁcations [22,38]. A recent online survey accordingly
revealed that only 4% of centers still use it for estimating the pheno-
type of their patients [23].
2.2. Phenotypes
Depending on the enzyme defect, the genotype and the severity of
the disease, different forms of PKU with different clinical phenotypes
have been described. Thus, different classiﬁcations for PKU pheno-
types have been established. PKU may be classiﬁed as classic PKU
and as variant PKU which includes all milder forms of PKU, (i.e. mod-
erate PKU andmild PKU), as mild HPA or non-PKUHPA, and, addition-
ally, as BH4-responsive PKU [29,39,40]. Deﬁnition of PKU phenotypes
may be essential in establishing treatment options, e.g. new therapeu-
tic strategies, in counseling and in prediction of the outcome, and in
pregnancy. Pretreatment blood Phe levels, the individual Phe toler-
ance, and the clinical course of the disease may help to discriminate
the different phenotypes of PKU, but are not precise parameters and
the cut-offs for pretreatment levels collected during the ﬁrst 24–
48 h, as they relate to the different types of PKU, have to be newly
deﬁned.
2.3. Blood phenylalanine
In 1980, for theﬁrst time, blood Phe levelswere used to discriminate
between three different phenotypes of PKU [29]. Still, this classiﬁcation
of the various types of PAH deﬁciency is used for phenotyping PKU:
Classic PKU is deﬁned by presenting with Phe pretreatment levels
N1200 μmol/L, variant PKU with Phe pretreatment levels of 600–
1200 μmol/L, and mild HPA with Phe pretreatment levelsb600 μmol/L.More precisely, PAH deﬁciency may be classiﬁed into four different
phenotypes: classic PKU presenting with Phe pretreatment levels
N1200 μmol/L, moderate PKU with Phe pretreatment levels of 900–
1200 μmol/L, mild PKU with Phe pretreatment levels of 600–
900 μmol/L, and mild HPA with Phe pretreatment level b600 μmol/L
[38,39].
Although pretreatment Phe levels are indispensable for pheno-
typing PKU, they are dependent on some variables, e. g. on the tim-
ing of blood Phe measurement, on the neonatal catabolism, and on
the diet received at the time of blood sampling. Due to improvement
in newborn screening with an early blood sampling at day three of
life, patients with PKU are diagnosed much earlier, thus resulting
in signiﬁcantly lower pretreatment Phe levels. If pretreatment Phe
levels will be used for determining PKU phenotypes in the future,
this classiﬁcation needs to be adjusted. In day-to-day-practice, pre-
treatment blood Phe levels have been shown to be used for pheno-
typing patients with PKU in about 80% of the treatment centers [23].
2.4. Phenylalanine tolerance
Daily Phe tolerance has been established as a stable parameter for
phenotyping the various types of PAH deﬁciency [29]. Phe tolerance is
usually determined at the age of 5 years and indicates the amount of
daily Phe intake that a patient can tolerate without an increase of the
blood Phe level above the upper target range. Three different pheno-
types may be classiﬁed by using Phe tolerance: classic PKU with a Phe
tolerance b20mg/kg/day, variant PKU with a Phe tolerance of 20–
50mg/kg/day, and mild HPA with a Phe tolerance N50 mg/kg/day
[29]. More detailed is the classiﬁcation into four different phenotypes,
who deﬁnes classic PKU with a Phe tolerance b20 mg/kg/day (250–
300 mg/day), moderate PKU with a Phe tolerance of 20–25 mg/kg/day
(350–400 mg/day), mild PKU with a Phe tolerance of 25–50 mg/kg/
day (400–600 mg/day), and mild HPA with patients off diet [38,39].
Recently it has been shown that Phe tolerance may be predictable
already at the age of 2 years, and that Phe tolerance at age 2, 3, and
5 years correlates with that at age 10 years [41]. In contrast, reassess-
ment of Phe tolerance may be necessary in adults [42]. Although Phe
tolerance is a good indicator for the PKU phenotype, its determination
may be unreliable if not determined under standardized conditions.
In day-to-day-practice, prescribed Phe intake often is much lower
than the effective Phe intake at home. We therefore recommend de-
termining Phe tolerance under standardized in-patient conditions
with precise dietary protocols. In clinical follow-up, Phe tolerance is
used for phenotyping patients with PKU in 70% of metabolic centers
queried [21].
2.5. Clinical course
Furthermore, various types of PAH deﬁciency may be distin-
guished by the clinical course of the disease. This includes data on
the outcome (e. g. education, IQ), the maximum blood Phe concentra-
tions (e. g. during febrile infection, dietary non-compliance), the ﬂuc-
tuation of blood Phe levels, and the Phe/Tyr ratios [43,44]. Though, in
day-to-day-practice, clinical course of the disease is only used in 31%
of metabolic centers to distinguish different PKU forms [23].
In day-to-day practice, classiﬁcation of PKU is essential for choos-
ing the optimal treatment. This may suggest a simpliﬁed classiﬁcation
scheme based on treatment requirements: a) patients who do need
strict dietary treatment (PKU), b) patients who do not need any treat-
ment (non-PKU HPA), c) patients who may be treated with BH4
(BH4-responsive PKU).
2.6. Software and phenylalanine home monitoring device
The Blaskovics loading tests at 6 months with their resulting 72 h
Phe values [32] yield indicators ofmetabolic phenotypeswhich belong
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respectively [33,34], thus establishing a classiﬁcation into classic and
variant PKU. A more detailed separation of the metabolic phenotypes
was established by Güttler and Guldberg [45] through estimating
Phe tolerance at 5 years of age (see also above). Neither of these sys-
tems can, at any age, predict the individual Phe tolerance. This is
made possible, however, by mathematical analysis of the data with a
kinetic model using per cent body water (PBW), net protein synthe-
sis (PROT), and 1st order rate of metabolic disposal (KOUT) of Phe
as variable parameters [46]. Both PBW and PROT are age-dependent
parameters, whereas KOUT is expected not to change with age.
With age-speciﬁc PBW and PROT data from the literature [47], an
age-independent KOUT would enable the reliable prediction of evolu-
tion of Phe tolerance at all ages. Even in adults, from their Blaskovics
test data, provided the patients, or their data, can be ‘retrieved’ again
[48].
By kinetic analysis of the protein loading data of the German PKU
Study it has been possible to explain the type 2 response as a conse-
quence of mutant PAH activation by high Phe levels [36]. Also some
mild cases, originally classiﬁed as type 1, were found to be activated
by Phe levels to some extent. The distribution of the KOUT estimates,
including the maximal KOUT estimates of the cases with activation, is
depicted in Fig. 3. This distribution is apparently multimodal and the
peaks appear to represent classic (a), moderate (b), and mild PKU (c),
and mild HPA (d), respectively. These ﬁndings can be compared to
the classiﬁcation of Güttler and Guldberg [45] by treating the dietary
tolerance at the target Phe level as the equilibrium state of Phe me-
tabolism. In the kinetic model [46] this corresponds to:
Target Phe ¼ intake–PROTð Þmg=dayð Þ=PBW T KOUT=day ð1Þ
With Eq. (1) and taking PBW=0.65 and PROT=2.7 mg Phe per kg
body weight and day, the classiﬁcation of Güttler and Guldberg trans-
lates into KOUT values of 0.62 and 1.08 per day for moderate and mild
PKU, respectively. The data at KOUT=1.7 (d) corresponds within this
system to an equilibrium Phe level of 110 μmol/L at an intake of
120 mg Phe per kg body weight and day (here taken as ‘normal diet’).
These calculations implicate that the constant of metabolic dispos-
al of Phe is about identical between 6 months and 5 years of age and
may therefore be considered as a patient-speciﬁc parameter. This is
relevant for the day-to-day management of PKU children, becauseFig. 3. Distribution of KOUT [per day], the 1st order rate constant of metabolic disposal
of Phe, in the German PKU Study [36], N=157. The data suggest the peaks a, b, c, and d
as representing classic, moderate and mild PKU, and mild HPA, respectively. The appar-
ently multimodal distribution implies a frequency in the German population of 15%
and 8% for mild PKU and mild HPA, respectively. Normal KOUT values, determined by
i.v. loads, range from 10.6 to 24.9 per day, corresponding to a half-life of 0.7 to 1.6 h.it has been shown (in an observational study) that increased Phe
values, in a considerable part of cases, are the consequence of hidden
catabolism (as indicated in the model by diminished PROT values)
and not of non-compliance [49].
Application of this kinetic model in a user-friendly format (e.g. a
so-called App) would support self-control with home-monitoring de-
vices [50] and could be trained e.g. in PKU summer camps. Such a de-
vice is presently in development and according to a recent survey
[23], 85% would consider home monitoring of Phe useful for both
children and pregnant women.
3. Genetics
3.1. PAH mutations and PKU genotypes (incl. databases)
As already stated, knowing whether a patient has residual PAH en-
zyme activity can be relevant for the therapeutic approach, the likely
Phe tolerance, and the expected response to BH4. Delineation of the
mutations of the PAH gene was initiated immediately after the clon-
ing of the gene in 1983 [28]. Initially the most prevalent mutations
in the Western European population were identiﬁed and character-
ized with regard to the in vitro residual enzyme activity associated
with the respective mutation [51,52]. Subsequently a ‘Phenylalanine
Hydroxylase Locus Knowledgebase’ PAHdb was created and curated
at McGill University [53] (http://www.pahdb.mcgill.ca/) that cata-
loged knowledge about PAH alleles and mutations and their charac-
teristics as reported by clinicians and laboratories from around the
world. This database now lists a total of 564 PAH mutations discov-
ered world wide as well as the knowledge available about the respec-
tive mutation including the residual enzyme activities of ~200
mutations. Of the 564 mutations 60.5% are missense mutations,
13.5% deletions, 11% splice site mutations, (5.7% silent mutations),
5% nonsense mutations, and 1.8% insertions. It was evident early on
that the majority of the PAH mutations were missense mutations
not preventing transcription or translation and that the majority of
the patients are compound heterozygotes, meaning they carry a dif-
ferent mutation in each of their alleles. PAH deﬁciency thus most
often results from complex interactions of mutant alleles or rapid in-
tracellular destruction of mutant enzyme subunits making genotype/
phenotype correlations based on the knowledge about individual mu-
tations challenging.
3.2. Phenotype–genotype correlation
The ﬁrst publication with extensive data on genotype/phenotype
correlation in PKU was able to establish that the genotype of the pa-
tient correlates with the biochemical phenotype [54]. PKU patients
had been tested for 8 mutations of the PAH gene for which the in
vitro residual enzyme activity had been determined. This mutation
analysis had allowed for complete genotype determination (identify-
ing both mutations) in 104 patients with PAH deﬁciency. Stringent
classiﬁcation criteria for the biochemical phenotype were applied to
determine genotype/phenotype correlation in these 104 patients.
There was a highly signiﬁcant correlation between the genotype
of the patients and the biochemical phenotype (r=0.74–0.84,
pb0.001 depending on the parameter) although the genotype was
expressed as the predicted residual enzyme activity of the patient
and was calculated as the mean of the combined in vitro residual en-
zyme activities of both mutant alleles of the patient, which was quite
a simpliﬁcation compared to the real in vivo situation. The goal of the
research had been to determine whether genotype analysis after ex-
clusion of BH4 cofactor deﬁciency could replace more involved clini-
cal testing such as response to a standardized oral protein load at
6 months of age and Phe tolerance assessment in an inpatient setting
over the course of 1–2 weeks at 5 years of age. These clinical tests had
proven to be the most reliable clinical classiﬁcation criteria in large
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ing test exposed the patient to high Phe concentrations.
In 1998 Guldberg at al. [38] reported the identiﬁcation of the com-
plete genotype in 686 patients from 7 European centers. Based on the
Phe tolerance (or in the case of mild HPA the pretreatment level) of
297 functionally hemizygous patients (patients carrying a null allele
and the uncharacterized mutant allele), an arbitrary phenotype cate-
gory was assigned to each of 105 mutations for which the residual en-
zyme activity was not known. Using these arbitrary categories
phenotype predictions for 650 of the patients were made. In 79% of
the patients the predicted phenotype matched the observed pheno-
type and the authors concluded that differences in the phenotype
classiﬁcation across centers might have accounted for the geno-
type–phenotype inconsistencies that were observed. Overall, despite
the potential shortcomings, this work also led to the conclusion that
the genotype is the main determinant of the biochemical phenotype
in most patients with PAH deﬁciency.
Many more studies were published reporting genotype/phenotype
correlations in different populations and inconsistencies, i.e. genotypes
that were associated with several different phenotypes. It was also
pointed out in numerous publications (ﬁrst by S. Kaufman [55]) and
investigated in vitro [56] that the combination of the twomutant alleles
is important for the residual PAH enzyme activity and that the individ-
ual mutations of a patient should not be viewed by themselves. It is
clear that the residual activity of an enzyme that is a homotetramer
that consists of a combination of different mutant subunits may not
simply be the mean of the activity that each subunit produces by itself
in vitro because there may be negative intra-allelic complementation
between different mutant enzyme subunits [55]. However, a correlation
between genotype and biochemical phenotype prevailed in the majority
of thepatients reported. Limitations regarding genotype-basedprediction
of the phenotype, however, are that the in vitro residual enzyme activ-
ity is not known for all mutations, that negative intra-allelic comple-
mentation may occur, and some exceptions described below may
occur.
3.3. BH4-responsive mutations and genotypes
As mentioned above a ‘Phenylalanine Hydroxylase Locus Knowl-
edgebase’ PAHdb exists at McGill University [53] (http://www.pahdb.
mcgill.ca/) that has catalogued knowledge about PAH alleles and muta-
tions including the associated phenotype. It lists the phenotype associ-
ated with about 600 allele combinations; however this data is ‘self-
reported’ by clinicians and laboratories using variable criteria for the de-
termination of the phenotype. Another database, the BIOPKU database
(www.biopku.org)was created at theUniversity of Zürich. It has catalo-
gued the complete genotypes (complete mutation combinations) of
730 PKU patients, their phenotypes (based on the highest blood Phe
levels before starting treatment) and their response to BH4. These 730
patients represent a total of 430 different mutation combinations.
Some of themutation combinations of the 730 patients listed are not
always associated with the same phenotype. Mutations for which in-
consistencies regarding genotype/phenotype correlation are reported
in this database as well as in the literature are the R261Q mutation in
the homozygous state or in combination with the R158Q mutation,
the L48S mutation in the homozygous state or in combination with
the R158Q mutation, and the Y414C mutation in combination with
the R408W mutation. However, although different phenotypes are as-
sociated with these mutation combinations their BH4 responsiveness
is always the same except in a smaller percentage of L48S homozygotes
(19%) that may not respond while 81% respond. A similar phenomenon
was observed in 40% of Turkish patients that were homozygous for the
E390G mutation and did not respond to BH4 [22] while other homozy-
gous patients and all patients compound heterozygous for this very
mild mutation listed in the BIOPKU database did respond to BH4.
The observations regarding variability for two mild mutations in thehomozygous state indicate that certain mutant homotetramers may
not allow for stable active enzyme even if the mutations themselves
appeared to be mild in vitro. Patients homozygous for these particular
mutations may occasionally not respond to BH4 or not within 48 h. Fi-
nally, for the c.1066-11GNAmutation in the homozygous state different
phenotypes and the whole spectrum of BH4 responsiveness (negative,
positive, and slow) is cataloged. Given that this is a mutation in an in-
tron that creates a cryptic splice acceptor site it is conceivable that the
cryptic splice site does not always come into play and functional en-
zyme is being translated under certain circumstances creating this
variability.
General truths about genotype/phenotype correlations in PKU that
have emerged from the data cataloged in the data bases, especially in
the BIOPKU data base are:
1. Mutation combinations that allow for b15% in vitro enzyme activ-
ity cause classic PKU and do not respond to BH4. Mutation combi-
nations that allow for N20% residual activity responds to BH4.
Responders have moderate to mild phenotypes.
2. Splice site mutations may cause classic or mild PKU depending on
‘read through’ (i.e. normal splicing may sometimes occur despite
the mutation), and the fact that they have different phenotype as-
sociations is listed in the available data bases.
3. Speciﬁc mild mutation/classic mutation combinations with identical
predicted residual enzyme activitymay have different phenotype as-
sociations (due to negative intra-allelic complementation) but the
phenotype associations of different mutation combinations can be
found in the available data bases making prediction unnecessary.
4. The BH4 responsiveness of many mutation combinations (com-
plete genotypes) has been well established multiple times. Pa-
tients that have those genotypes may not need to undergo BH4
responsiveness testing.
After assessment of the genotype (both mutations) of a patient
one can now in many cases simply look up the associated phenotype
and BH4 responsiveness that is cataloged for this mutation combina-
tion in the databases rather than trying to predict it using a simplify-
ing formula and the in vitro residual enzyme activity of the mutant
alleles as was done in the past and had its limitations (see above).
DNA diagnostic laboratories should include the information cataloged
in the data bases for a speciﬁc mutation combination in their reports
about PAH mutations to clinicians to allow physicians to make the
best informed decisions based on available information.
In an anonymous survey among 65 US metabolic centers 72% of
the centers reported that they classify PKU patients into classic PKU,
mild PKU, and mild HPA; 40% were ordering mutation testing on all
of their patients 53% on some of their patients; 53% of the centers
order genotype analysis, when they order it, to understand the phe-
notype of the patient; 72% order to provide the family with genetic in-
formation (multiple answers could be chosen); of those who do not
order mutation analysis 40% said they had too little information
about the meaning of the mutations (what phenotype to expect),
54% said they do not need mutation analysis to understand the phe-
notype of their patients, and 36% said the health insurance of their pa-
tients does not cover the testing; 20% of the centers said they order
mutation analysis on each PKU patient that wants to try BH4 supple-
mentation to see whether the patient should have residual enzyme
activity (which would make it more likely that patient responds to
BH4).
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